Last reviewed · How we verify
0.15% sodium Hyaluronate
At a glance
| Generic name | 0.15% sodium Hyaluronate |
|---|---|
| Sponsor | Innovative Medical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Ocular Lubricants in People With Symptoms of Dry Eye (PHASE4)
- Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. (PHASE4)
- Protecting the Eyes of Gamers With Lubricating Eyedrops (NA)
- Cord Blood Platelet Poor Plasma Eye Drops (NA)
- Potential Role of Ocular Surface Microbiome in Dry Eye: Microbial Interactions and Symptom Alleviation (NA)
- Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF (PHASE1)
- Evaluation of Dexpanthenol and Hyaluronic Acid Eye Drops on Corneal Epithelialization After Trans Epithelial PRK (PHASE4)
- Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |